#USA #Florida #Dementia #Creyos #Claremedica

Creyos' Digital Cognitive Testing Transforming Dementia Detection

In recent months, a significant advancement in dementia detection has emerged from the partnership between Creyos and Claremedica, a primary care organization in Florida. This collaboration aims to revolutionize the way cognitive impairments, particularly dementia, are diagnosed in senior care facilities. Utilization of Creyos' digital cognitive assessment tool has shown an impressive ability to identify over 90% of new dementia cases at the earliest stages, significantly enhancing preventive care strategies for patients at risk.

The Shift to Digital

For decades, many primary care providers have relied on traditional paper-based screening methods such as the Mini-Mental State Exam (MMSE) to assess cognitive function. While these methods had been effective for identifying moderate to severe cognitive decline, they often overlooked early signs of dementia. Claremedica, understanding the need for timely and accurate assessments, transitioned to Creyos' digital cognitive screening tools. This has resulted in more than doubling their identification rates of dementia, particularly at stages where intervention can most effectively slow progression.

Key Findings and Impact

During the first seven months following the switch to Creyos’ assessment tools, Claremedica successfully detected a staggering 90% of new dementia cases, focusing on mild and early stages. This contrasts sharply with the national statistic where over 60% of cognitive impairments go unidentified in primary care settings. An alarming trajectory is projected for dementia, with estimates indicating that the number of Americans living with Alzheimer's disease may rise from 7 million today to 13 million by 2050. Therefore, the implementation of early detection systems is crucial.

Dr. Nehal Gheewala, Claremedica's Chief Medical Officer, emphasized the importance of addressing cognitive health similarly to vital signs such as blood pressure or heart rate. He noted that cognition, like physical health metrics, changes subtly over time and requires equal attention from healthcare providers. Different from the older exam formats that provided binary pass/fail results, Creyos offers a nuanced profile of cognitive abilities including memory, attention, reasoning, and executive functions.

Streamlining the Assessment Process

One of Creyos’ significant advantages lies in its efficiency. The assessment process has been streamlined, reducing the average screening time from approximately 12 minutes with traditional methods to just six minutes. This not only increases the number of patients screened but also optimizes a physician's daily workload, allowing them to focus on direct patient care.

Additionally, Creyos is designed to be accessible, operating in 13 different languages–a critical feature for Claremedica's diverse patient population in Florida. The digital platform integrates seamlessly with over 90 electronic health record systems, reaffirming its usefulness in modern medical practices.

Encouraging Physician Engagement

The successful implementation of the Creyos system within Claremedica can be attributed to strong physician engagement. An impressive initial adoption rate of 95% was achieved when the platform was launched. Claremedica organized a comprehensive informational session featuring Creyos’ co-founder, Professor Adrian Owen. His presentation highlighted the robust research backing their platform, aiming to build clinician confidence and trust in the new system before any patient screenings began.

With Claremedica's commitment to leading the charge in cognitive care, they have demonstrated that understanding and managing cognitive decline is not only possible but imperative. The results indicate that this technology does not just aid patients and caregivers but also fundamentally rethinks how primary healthcare addresses cognitive health.

Future Directions

Looking ahead, Claremedica is keen to continue its research into how early identification of dementia correlates with patient outcomes. This encompasses factors like fall incidents, avoidable hospital admissions, and overall costs associated with care. Tracking these metrics will help solidify the long-term benefits of their early detection methodologies.

The partnership between Creyos and Claremedica serves as a prototype for how technology can enhance health outcomes among seniors, creating a pathway for more proactive approaches to cognitive health. For more information about their partnership and the tools involved, visit Creyos' website.

Conclusion

Ultimately, the adoption of digital cognitive testing by Claremedica is not just a win for early dementia detection; it signifies a transformation in the healthcare sector's approach to aging populations. As the prevalence of cognitive disorders escalates, implementing innovative solutions like Creyos could prove pivotal in not only identifying but effectively managing these conditions, leading to improved life quality for countless individuals.